How does Prof. Wu Yiling promote the transformation of scientific and technological achievements in Chinese medicine?

For more than 40 years, Prof. Wu Yiling has established a theoretical system of complex disease consisting of the evidence and treatment of complex disease, the doctrine of veins and collaterals and the doctrine of qi and collaterals***similar to the theoretical theory, and continuously applies the theoretically innovated prescriptions to the clinic, and transforms clinically verified and effective prescriptions into new medicines, and then industrializes the new medicines. At present, Ealing Pharmaceuticals has developed innovative and patented Chinese medicines such as Tongxinluo Capsule, Ginseng Pine Nourishing Heart Capsule and Lianhua Qingdian Capsule/Pellet. Meanwhile, Prof. Wu Yiling and his team have also adopted the internationally recognized randomized, double-blind, multi-center clinical evidence-based medical evaluation methodology, pioneering evidence-based research in TCM. Not long ago, a clinical evidence-based study on Chinese Tongxinluo's treatment of acute myocardial infarction and improvement of patients' prognosis, conducted by Prof. Yang Yuejin of Beijing Fuwai Hospital, was published in JAMA, a top international medical journal. The results of the study show that Tongxinluo, an innovative Chinese medicine from Ealing, can significantly improve the 30-day and 1-year clinical prognosis of patients with ST-segment elevation myocardial infarction (STEMI).